Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Degarelix PK/PD and Safety Study in Prostate Cancer
NCT00117949Phase 2Completed
- Sponsor
- Ferring Pharmaceuticals
- Start
- Apr 2002
- Primary completion
- Jan 2004
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of degarelix in prostate cancer (PCa) (4 arms), sponsored by Ferring Pharmaceuticals. Primary endpoints: Time to Meet Insufficient Testosterone Response at 3 months and Number of Participants With Testosterone Serum Levels Below 0.5 ng/mL for at Least 28 Days. Started Apr 2002; status: completed.
02
Drugs
degarelix
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00117949.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00117949.